Global /Japan /Industrials /Specialty Business Services /4599

StemRIM

4599

• TSE: 4599 • Delayed

300JPY -0.3%

1.87 USD

As of 5 June 2026, StemRIM has a market cap of $117.89M USD, ranking #24420 globally and #2105 in Japan. It ranks #5645 in the Industrials sector, and #627 in the Specialty Business Services industry.

Global Rank

24420

Country Rank

2105

Sector Rank

5645

Industry Rank

627

Key Stats

Market Cap

$117.89MUSD

18.87B JPY

Enterprise Value

$79.14MUSD

12.67B JPY

EBITDA (TTM)

-$11.54MUSD

-1.85B JPY

Net Income (TTM)

-$11.3MUSD

-1.81B JPY

PB Ratio

2.9

Company Profile

Country (HQ)

Japan

Sector

Industrials

Industry

Specialty Business Services

CEO

Masatsune Okajima open_in_new

Employees

Founded

2006

Website

stemrim.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-0.3%	-2.9%	-1%	1.7%	10%	14%	-9.4%	-76%	-63%

Upcoming Earnings

Earnings Date

Wed, Jun 10

News

Markets

Exchange	Ticker	Price	Quotes
Tokyo Stock Exchange (TSE / TYO) MIC: XTKS PRIMARY	4599 ステムリム ISIN: JP3399690001 Shares Out.: Shares Outstanding: 62.681M¹ Shares Float: 26.311M² TV: TradingView: TSE: 4599 SA: Stock Analysis: TYO: 4599 YF: Yahoo Finance: 4599.T GF: Google Finance: TYO: 4599 BA: Barron's: 4599 MS: Morningstar: XTKS: 4599	300 JPY	TV: TradingView: TSE: 4599 SA: Stock Analysis: TYO: 4599 YF: Yahoo Finance: 4599.T GF: Google Finance: TYO: 4599 BA: Barron's: 4599 MS: Morningstar: XTKS: 4599

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About StemRIM

StemRIM, a biotechnology company, researches and develops regeneration-inducing medicine in Japan and internationally. The company offers TRIM2, a peptide drug, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, myocardial infarction/cardiomyopathy, liver cirrhosis, and knee osteoarthritis. It also provides pre-clinical stage products, including TRIM3 and TRIM4 for the treatment of various tissue damage diseases; and TRIM5, a molecule for tissue repair, as well as SR-GT1, a stem cell gene therapy. The company was incorporated in 2006 and is headquartered in Ibaraki, Japan.

Similar Companies

Industry: Specialty Business Services (Japan)

Name	Market Cap (USD) diff.	PE	Country
SECOM CO., LTD. TSE: 9735	$14.55B 2.33T JPY 12K%	22.1	Japan
PayPay Corp. NASDAQ: PAYP	$13.65B 11K%	17.5	Japan
Eisai Co., Ltd. TSE: 4523	$8.11B 1.3T JPY 7K%	30.4	Japan
Baycurrent, Inc. TSE: 6532	$4.97B 795.87B JPY 4K%	21.0	Japan
Alsok Co.,Ltd. TSE: 2331	$3.66B 585.61B JPY 3K%	17.4	Japan
Visional, Inc. TSE: 4194	$1.87B 300.04B JPY 1K%	17.3	Japan

Industry: Specialty Business Services (Global)

Name	Market Cap (USD) diff.	PE	Country
Shopify Inc. NASDAQ: SHOP	$158.14B 134K%	129.8	Canada
Verisure plc STO: VSURE	$133.15B 114.8B EUR 113K%	-	United Kingdom
Cintas Corp. NASDAQ: CTAS	$69.6B 59K%	36.8	United States
RELX PLC LSE: REL	$63.87B 47.6B GBP 54K%	23.9	United Kingdom
PayPal Holdings, Inc. NASDAQ: PYPL	$45.83B 39K%	9.4	United States
T Thomson Reuters Corp. NEO: TRI	$41.8B 56.91B CAD 35K%	-	Canada

chevron_leftBack